

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Thomas Ivo Cremers, et al. Confirmation No. 5528
Application No.: 10/596,348 Group Art Unit: 3762
Filed: July 14, 2006 Examiner: Not yet assigned
For: COMBINATION OF A SEROTONIN REUPTAKE INHIBITOR AND
A HISTAMINE 3 RECEPTOR ANTAGONIST, INVERSE AGONIST
OR PARTIAL AGONIST

Date: September 18, 2007

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In compliance with the duty of disclosure under 37 C.F.R. § 1.56 and in accordance with the practice under 37 C.F.R. §§ 1.97 and 1.98, the Examiner's attention is directed to the documents listed on the enclosed Information Disclosure Statement by Applicant form (PTO/SB/08a). Copies of the three (3) cited U.S. Patent Application Publication documents have not been submitted (37 C.F.R. § 1.98 (a)(2)(ii)).

It is respectfully requested that the above information be considered by the Examiner and that an initialed copy of the accompanying Information Disclosure Statement by Applicant form (PTO/SB/08a) be returned to the undersigned indicating that such information has been considered.

This Supplemental Information Disclosure Statement is being filed before the mailing of a first Office action on the merits. Accordingly, neither a fee nor Statement under 37 C.F.R. § 1.97(e) is due. However, if a first Office Action has been mailed, authorization is given to charge the fee under 37 C.F.R. § 1.17(p) (\$180) to Deposit Account No. 50-3201.

If a telephone interview would be of assistance in advancing prosecution of the above-identified application, Applicant's undersigned agent invites the Examiner to telephone the number provided below.

Respectfully submitted,

/Kitae Lim Reg. # 58,066/
Kitae Lim
Lundbeck Research USA, Inc.
215 College Road
Paramus, New Jersey 07652
Tel: 201-350-0782
Fax: 201-225-9571